223 related articles for article (PubMed ID: 31837803)
1. Dexrazoxane ameliorates doxorubicin-induced cardiotoxicity by inhibiting both apoptosis and necroptosis in cardiomyocytes.
Yu X; Ruan Y; Huang X; Dou L; Lan M; Cui J; Chen B; Gong H; Wang Q; Yan M; Sun S; Qiu Q; Zhang X; Man Y; Tang W; Li J; Shen T
Biochem Biophys Res Commun; 2020 Feb; 523(1):140-146. PubMed ID: 31837803
[TBL] [Abstract][Full Text] [Related]
2. Dexrazoxane Protects Cardiomyocyte from Doxorubicin-Induced Apoptosis by Modulating miR-17-5p.
Yu X; Ruan Y; Shen T; Qiu Q; Yan M; Sun S; Dou L; Huang X; Wang Q; Zhang X; Man Y; Tang W; Jin Z; Li J
Biomed Res Int; 2020; 2020():5107193. PubMed ID: 32190669
[TBL] [Abstract][Full Text] [Related]
3. Humanin analog enhances the protective effect of dexrazoxane against doxorubicin-induced cardiotoxicity.
Lue Y; Gao C; Swerdloff R; Hoang J; Avetisyan R; Jia Y; Rao M; Ren S; Atienza V; Yu J; Zhang Y; Chen M; Song Y; Wang Y; Wang C
Am J Physiol Heart Circ Physiol; 2018 Sep; 315(3):H634-H643. PubMed ID: 29775411
[TBL] [Abstract][Full Text] [Related]
4. Cardiac protective effects of dexrazoxane on animal cardiotoxicity model induced by anthracycline combined with trastuzumab is associated with upregulation of calpain-2.
Zhang S; Meng T; Liu J; Zhang X; Zhang J
Medicine (Baltimore); 2015 Jan; 94(4):e445. PubMed ID: 25634181
[TBL] [Abstract][Full Text] [Related]
5. The Role of Topoisomerase IIβ in the Mechanisms of Action of the Doxorubicin Cardioprotective Agent Dexrazoxane.
Hasinoff BB; Patel D; Wu X
Cardiovasc Toxicol; 2020 Jun; 20(3):312-320. PubMed ID: 31773441
[TBL] [Abstract][Full Text] [Related]
6. A QSAR study that compares the ability of bisdioxopiperazine analogs of the doxorubicin cardioprotective agent dexrazoxane (ICRF-187) to protect myocytes with DNA topoisomerase II inhibition.
Hasinoff BB; Patel D; Wu X
Toxicol Appl Pharmacol; 2020 Jul; 399():115038. PubMed ID: 32417440
[TBL] [Abstract][Full Text] [Related]
7. Investigation of Structure-Activity Relationships of Dexrazoxane Analogs Reveals Topoisomerase II
Kollárová-Brázdová P; Jirkovská A; Karabanovich G; Pokorná Z; Bavlovič Piskáčková H; Jirkovský E; Kubeš J; Lenčová-Popelová O; Mazurová Y; Adamcová M; Skalická V; Štěrbová-Kovaříková P; Roh J; Šimůnek T; Štěrba M
J Pharmacol Exp Ther; 2020 Jun; 373(3):402-415. PubMed ID: 32253261
[TBL] [Abstract][Full Text] [Related]
8. Role of hypoxia-inducible factors in the dexrazoxane-mediated protection of cardiomyocytes from doxorubicin-induced toxicity.
Spagnuolo RD; Recalcati S; Tacchini L; Cairo G
Br J Pharmacol; 2011 May; 163(2):299-312. PubMed ID: 21232037
[TBL] [Abstract][Full Text] [Related]
9. Astragalus polysaccharide restores autophagic flux and improves cardiomyocyte function in doxorubicin-induced cardiotoxicity.
Cao Y; Shen T; Huang X; Lin Y; Chen B; Pang J; Li G; Wang Q; Zohrabian S; Duan C; Ruan Y; Man Y; Wang S; Li J
Oncotarget; 2017 Jan; 8(3):4837-4848. PubMed ID: 27902477
[TBL] [Abstract][Full Text] [Related]
10. Regulated cell death pathways in doxorubicin-induced cardiotoxicity.
Christidi E; Brunham LR
Cell Death Dis; 2021 Apr; 12(4):339. PubMed ID: 33795647
[TBL] [Abstract][Full Text] [Related]
11. Acetylcholinesterase inhibitor ameliorates doxorubicin-induced cardiotoxicity through reducing RIP1-mediated necroptosis.
Khuanjing T; Ongnok B; Maneechote C; Siri-Angkul N; Prathumsap N; Arinno A; Chunchai T; Arunsak B; Chattipakorn SC; Chattipakorn N
Pharmacol Res; 2021 Nov; 173():105882. PubMed ID: 34530122
[TBL] [Abstract][Full Text] [Related]
12. Protective effects of necrostatin-1 on doxorubicin-induced cardiotoxicity in rat heart.
Erdogmus Ozgen Z; Erdinc M; Kelle İ; Erdinc L; Nergiz Y
Hum Exp Toxicol; 2022; 41():9603271211066066. PubMed ID: 35137609
[No Abstract] [Full Text] [Related]
13. Thrombopoietin protects against in vitro and in vivo cardiotoxicity induced by doxorubicin.
Li K; Sung RY; Huang WZ; Yang M; Pong NH; Lee SM; Chan WY; Zhao H; To MY; Fok TF; Li CK; Wong YO; Ng PC
Circulation; 2006 May; 113(18):2211-20. PubMed ID: 16651473
[TBL] [Abstract][Full Text] [Related]
14. Quantifying Drug-Induced Nanomechanics and Mechanical Effects to Single Cardiomyocytes for Optimal Drug Administration To Minimize Cardiotoxicity.
Yue T; Park KH; Reese BE; Zhu H; Lyon S; Ma J; Mohler PJ; Zhang M
Langmuir; 2016 Feb; 32(7):1909-19. PubMed ID: 26738425
[TBL] [Abstract][Full Text] [Related]
15. Neonatal murine engineered cardiac tissue toxicology model: Impact of dexrazoxane on doxorubicin induced injury.
Zhen J; Yu H; Ji H; Cai L; Leng J; Keller BB
Life Sci; 2019 Dec; 239():117070. PubMed ID: 31751580
[TBL] [Abstract][Full Text] [Related]
16. SIRT1 suppresses doxorubicin-induced cardiotoxicity by regulating the oxidative stress and p38MAPK pathways.
Ruan Y; Dong C; Patel J; Duan C; Wang X; Wu X; Cao Y; Pu L; Lu D; Shen T; Li J
Cell Physiol Biochem; 2015; 35(3):1116-24. PubMed ID: 25766524
[TBL] [Abstract][Full Text] [Related]
17. Catalytic inhibitors of topoisomerase II differently modulate the toxicity of anthracyclines in cardiac and cancer cells.
Vavrova A; Jansova H; Mackova E; Machacek M; Haskova P; Tichotova L; Sterba M; Simunek T
PLoS One; 2013; 8(10):e76676. PubMed ID: 24116135
[TBL] [Abstract][Full Text] [Related]
18. Cardiomyocyte-specific disruption of Cathepsin K protects against doxorubicin-induced cardiotoxicity.
Guo R; Hua Y; Ren J; Bornfeldt KE; Nair S
Cell Death Dis; 2018 Jun; 9(6):692. PubMed ID: 29880809
[TBL] [Abstract][Full Text] [Related]
19. Dexrazoxane (ICRF-187) protects cardiac myocytes against doxorubicin by preventing damage to mitochondria.
Hasinoff BB; Schnabl KL; Marusak RA; Patel D; Huebner E
Cardiovasc Toxicol; 2003; 3(2):89-99. PubMed ID: 14501028
[TBL] [Abstract][Full Text] [Related]
20. C1qTNF-related protein 1 attenuates doxorubicin-induced cardiac injury via activation of AKT.
Chen H; Gao L; Huang Z; Liu Y; Guo S; Xing J; Meng Z; Liang C; Li Y; Yao R; Li L; Zhang Y; Gu H; Liu Y
Life Sci; 2018 Aug; 207():492-498. PubMed ID: 29964055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
